TW252045B - - Google Patents

Info

Publication number
TW252045B
TW252045B TW082109287A TW82109287A TW252045B TW 252045 B TW252045 B TW 252045B TW 082109287 A TW082109287 A TW 082109287A TW 82109287 A TW82109287 A TW 82109287A TW 252045 B TW252045 B TW 252045B
Authority
TW
Taiwan
Application number
TW082109287A
Other languages
Chinese (zh)
Original Assignee
Allan L Goldstein
Mirela O Fagarasan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allan L Goldstein, Mirela O Fagarasan filed Critical Allan L Goldstein
Application granted granted Critical
Publication of TW252045B publication Critical patent/TW252045B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW082109287A 1993-10-07 1993-11-05 TW252045B (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13285993A 1993-10-07 1993-10-07

Publications (1)

Publication Number Publication Date
TW252045B true TW252045B (en:Method) 1995-07-21

Family

ID=22455918

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082109287A TW252045B (en:Method) 1993-10-07 1993-11-05

Country Status (4)

Country Link
US (1) US5585352A (en:Method)
MY (1) MY116338A (en:Method)
TW (1) TW252045B (en:Method)
ZA (1) ZA947751B (en:Method)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197751B1 (en) * 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
WO2002053142A2 (en) * 2001-01-05 2002-07-11 Metaphore Pharmaceuticals, Inc. Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
US20040132706A1 (en) * 2001-10-05 2004-07-08 Daniela Salvemini Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
WO2004048971A1 (en) * 2002-11-25 2004-06-10 Sciclone Pharmaceuticals, Inc. Methods of protecting against radiation damage using alpha thymosin
ATE467422T1 (de) * 2003-03-28 2010-05-15 Sciclone Pharmaceuticals Inc Behandlung von aspergillus-infektionen mit thymosin alpha 1
US20130296223A1 (en) * 2012-03-30 2013-11-07 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for the treatment of sepsis
USD982375S1 (en) 2019-06-06 2023-04-04 Sharkninja Operating Llc Food preparation device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4297276A (en) * 1979-03-23 1981-10-27 Hoffman-La Roche Inc. Thymosin beta 3 and beta 4
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock

Also Published As

Publication number Publication date
US5585352A (en) 1996-12-17
MY116338A (en) 2004-01-31
ZA947751B (en) 1996-04-04

Similar Documents

Publication Publication Date Title
DK52393D0 (en:Method)
EP0643122A3 (en:Method)
EP0637598A3 (en:Method)
EP0644696A3 (en:Method)
DK0698306T3 (en:Method)
FR2706901B1 (en:Method)
EP0702629A4 (en:Method)
EP0686452A4 (en:Method)
EP0710070A4 (en:Method)
DK21393D0 (en:Method)
EP0700547A4 (en:Method)
DK21494A (en:Method)
CZ101796A3 (en:Method)
FR2706869B1 (en:Method)
DK121593D0 (en:Method)
ECSDI930159S (en:Method)
ECSDI930165S (en:Method)
ECSDI930171S (en:Method)
ECSMU930023U (en:Method)
ECSMU930027U (en:Method)
ECSMU930028U (en:Method)
ECSDI930150S (en:Method)
ECSDI930144S (en:Method)
ECSDI930136S (en:Method)
ECSDI930135S (en:Method)

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees